Sanofi releases real world data on Toujeo in diabetes

15 June 2016

French drugmaker Sanofi (EPA: SAN) has presented the first real world data on the use of Toujeo (insulin glargine injection 300 Units/mL) at the 76th Scientific Sessions of the American Diabetes Association (ADA) in New Orleans.

The study, using the US Predictive Health Intelligence Environment (PHIE) database, examined electronic health records of 881 patients with type 2 diabetes to assess changes in HbA1c (average blood sugar levels) and occurrence of hypoglycaemia up to six months after switching to Toujeo from another basal insulin.

In a subpopulation of patients (267) with HbA1c and incidence of confirmed or severe hypoglycemia up to six months prior to and up to six months after initiation, mean HbA1c was 8.97% at baseline and 8.33% at follow-up (0-6 months).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK